Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline ...

Revenue from oncology products made up 43 per cent of Astrazeneca's revenue in the first half of 2025, up 15 per cent year on ...

Pharmaceutical giant AstraZeneca has reported increased revenue across all its major geographic regions and increased interim profits as the listed business maintained its growth ...

The Anglo-Swedish pharmaceutical giant said Tuesday that for the second quarter, core earnings per share rose to $2.17 from $1.98 in the same period a year prior. Revenue increased to $14.46 billion ...

Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year, driven by double-digit growth in Oncology ...

AstraZeneca PLC (NASDAQ: AZN) ranks among the stocks to benefit from an onshoring boom. AstraZeneca PLC (NASDAQ:AZN) ...

The FTSE 100 has started higher, up 13 points to 9,094 in a mixed early trading for European markets. Games Workshop Group ...

FTSE 100 Live Tuesday Barclays profit tops forecastsAstraZeneca backs 2025 guidanceGreggs hit by cost headwinds ...

(Alliance News) - AstraZeneca PLC on Tuesday reported better-than-expected second quarter revenue, and raised its dividend, boosted by strong sales from its cancer portfolio.

Despite the EU and US agreeing a basic trade deal on Monday, the FTSE 100 and some European stocks fell on the day after a ...

(Alliance News) - AstraZeneca raised its dividend as drug growth pushed earnings higher, Barclays launched a new buyback programme after profit jumped while Greggs saw profit fall despite higher sales ...